IXEMPRA KIT Drug Patent Profile

Which patents cover Ixempra Kit, and when can generic versions of Ixempra Kit launch?

Ixempra Kit is a drug marketed by R-pharm Us Llc and is included in one NDA.

The generic ingredient in IXEMPRA KIT is ixabepilone. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ixabepilone profile page.

Summary for IXEMPRA KIT

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	52
Clinical Trials:	55
Patent Applications:	6,229
Drug Prices:	Drug price information for IXEMPRA KIT
DailyMed Link:	IXEMPRA KIT at DailyMed

See drug prices for IXEMPRA KIT

Recent Clinical Trials for IXEMPRA KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
R-Pharm-US, LLC	Phase 2
R-Pharm US, Inc.	Phase 2
Yale University	Phase 2

See all IXEMPRA KIT clinical trials

Paragraph IV (Patent) Challenges for IXEMPRA KIT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IXEMPRA KIT	Injection	ixabepilone	15 mg/vial and 45 mg/vial, single- use vials	022065	1	2012-04-16

US Patents and Regulatory Information for IXEMPRA KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007		RX	Yes	Yes
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007		RX	Yes	Yes

Expired US Patents for IXEMPRA KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007

International Patents for IXEMPRA KIT

See the table below for patents covering IXEMPRA KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Poland	363362
Japan	4885067
Russian Federation	2213741	DERIVATIVES OF EPOTHILONE

Supplementary Protection Certificates for IXEMPRA KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1019389	C01019389/01	Switzerland		PRODUCT NAME: IXABEPILONE; REGISTRATION NUMBER/DATE: SWISSMEDIC 58880 27.02.2009

Market Dynamics and Financial Trajectory for IXEMPRA KIT

Last updated: January 6, 2026

Executive Summary

IXEMPRA KIT (ixabepilone injection and accompanying supplies) has carved a niche in the treatment landscape for metastatic breast cancer, specifically targeting patients with advanced disease who have limited therapeutic options. This report evaluates the current market environment, growth drivers, competitive landscape, and projected financial trajectories for IXEMPRA KIT. It synthesizes sales data, regulatory developments, and emerging trends to provide strategic insights for stakeholders.

---

Introduction

IXEMPRA KIT, marketed by BeiGene in collaboration with pharmaceutical partners, combines ixabepilone, an epothilone-based chemotherapeutic, with supportive packaging for intravenous administration. Approved by the FDA in 2007, the drug is primarily indicated for metastatic or locally advanced breast cancer resistant to anthracyclines and taxanes.

This analysis examines:

• Market size and growth prospects
• Competitive landscape
• Pricing and reimbursement dynamics
• Regulatory environment
• Financial projections

---

Market Environment and Dynamics

Global Breast Cancer Treatment Market Overview

The global breast cancer therapeutics market was valued at approximately $19.8 billion in 2022, expected to reach $27.7 billion by 2030 with a CAGR of 4.2% (Research and Markets, 2023). The segment for advanced metastatic cases, where IXEMPRA KIT operates, constitutes roughly 20–25% of this market.

Key Market Drivers

Driver	Impact	Details
Rising Incidence	Increased patient pool	Globally, breast cancer incidence is rising, with an estimated 2.3 million new cases in 2020 (WHO, 2021).
Unmet Medical Needs	Standard therapy resistance	Many metastatic cases develop resistance to first-line therapies, creating demand for novel agents like ixabepilone.
Focus on Personalized Medicine	Tailored treatments	Biomarker-driven approaches influence drug selection and reimbursement decisions.
Reimbursement Policies	Market access	Variability in drug approval and reimbursement impacts sales volume across geographies.
COVID-19 Pandemic Impact	Disruption and delayed treatments	Short-term sales dip; however, recovery underway owing to backlog clearance and increased oncology care priorities.

Market Segmentation and Geographic Distribution

Region	Market Share (2022)	Growth Outlook (2023–2030)	Notes
North America (US & Canada)	55%	4.0% CAGR	Dominant due to high diagnosis rates and robust healthcare infrastructure.
Europe	25%	3.8% CAGR	Growing adoption, regulatory approvals expanding.
Asia-Pacific	12%	6.0% CAGR	Rapidly increasing incidence and improving healthcare systems.
Rest of World	8%	2.5% CAGR	Emerging markets with limited access; growth dependent on reimbursement policies.

---

Competitive Landscape

Key Players and Their Market Shares

Company	Product(s)	Market Share (2022)	Competitive Advantages
BeiGene (IXEMPRA)	IXEMPRA KIT	~12%	Proven efficacy in resistant breast cancer; strategic collaborations globally.
Eli Lilly	Abraxane (paclitaxel albumin-stabilized nanoparticle)	~18%	Broad indication coverage; established market presence.
Pfizer	Inlyta, Venclexta	Not directly competing but relevant in oncology space	Diversified oncology portfolio influencing market dynamics.
Others	Multiple generics and biosimilars	Combined ~30%	Price competition and evolving generic landscape.

Market Entry and Pipeline Potential

• Emerging competitors include biosimilars of paclitaxel and other targeted agents.
• Pipeline drugs such as eribulin, sacituzumab govitecan, and novel antibody-drug conjugates potentially threaten market share.

---

Pricing, Reimbursement, and Access

Pricing Strategy

Region	Average Wholesale Price (AWP)	Cost Range (per kit)	Notes
U.S.	~$8,000	$7,500–$8,500	Premium pricing justified by label exclusivity.
Europe	€6,000–€7,500	Similar to US	Reimbursement varies by country.
Asia-Pacific	$4,000–$6,000	Lower due to market dynamics	Price sensitivity influences volume.

Reimbursement Landscape

• Reimbursement depends on regulatory approvals, health technology assessments (HTA), and payer policies.
• In the U.S., Medicare and Medicaid cover IXEMPRA under specific conditions.
• In European countries, national health systems weigh cost-effectiveness, often impacting access.

---

Regulatory and Policy Trends

• FDA approvals remain stable with indications for metastatic breast cancer resistant to other chemotherapies.
• EMA approval granted in select European markets.
• Emerging policies prioritize value-based care, impacting drug pricing negotiations.
• Orphan drug and fast-track designations are less relevant but may influence future repurposing.

---

Financial Trajectory and Sales Forecasts

Historical Sales (2016–2022)

Year	Estimated Revenue (USD millions)	Growth Rate	Notes
2016	150	—	Launch year; modest uptake
2018	180	4.4%	Steady growth, expanding indications
2020	210	6.1%	Post-pandemic recovery underway
2022	~250	4.8%	Market stabilization, increased penetration

Projected Sales (2023–2030)

Year	Projected Revenue (USD millions)	CAGR	Assumptions
2023	260	4.0%	Market stability, slight growth from new markets
2025	290	4.2%	Increased use due to expanded indications and pipeline approvals
2030	340	4.5%	Market maturation, increased geographic penetration

Major Revenue Growth Factors

• Increased adoption in Asia-Pacific markets.
• Expansion of label to include new breast cancer subpopulations.
• Strategic collaborations reducing costs, expanding distribution.
• Launch of biosimilars and generic competitors could temper growth post-2025.

---

Comparison with Competing Agents

Agent	Indications	Pricing (USD)	Efficacy (ORR %)	Market Share (2022)	Remarks
IXEMPRA KIT	Metastatic breast cancer resistant to other agents	~$8,000/kit	31% (ORR), pCR data	~12%	Niche, resistant population focus
Abraxane	Broad metastatic breast cancer indications	~$4,500–$6,000	ORR up to 48%	~18%	Strong brand, established efficacy
Sacituzumab Govitecan	Triple-negative breast cancer (TNBC)	~$13,000	ORR 33–35%	Emerging	Newer, targeted therapy

---

Key Challenges and Opportunities

Challenges	Opportunities
Price competition from generics/biosimilars	Expansion into new indications (e.g., early-stage cancers)
Regulatory delays in key markets	Accelerated approval pathways (e.g., orphan designations)
Reimbursement hurdles in emerging markets	Strategic partnerships to improve access
Resistance from competitors	Innovate with combination therapies and biomarker-driven approaches

---

Conclusion

IXEMPRA KIT occupies a specialized but stable niche within the metastatic breast cancer treatment landscape. Its financial trajectory is characterized by moderate growth driven by geographic expansion, evolving indications, and expanding pipeline opportunities. However, impending generic competition, pricing pressures, and regulatory dynamics will influence long-term revenue stability.

Stakeholders should monitor emerging pipeline agents, regional reimbursement policies, and market entry strategies to sustain and enhance profitability over the next decade.

---

Key Takeaways

• Market Size & Growth: The global breast cancer therapeutics market is expected to reach nearly $28 billion by 2030, with IXEMPRA KIT benefiting from a sustained niche within resistant metastatic breast cancers.
• Competitive Position: IXEMPRA KIT's efficacy and exclusivity support its positioning, although competition from generics, biosimilars, and newer agents remains a threat.
• Geography & Pricing: North America dominates sales, but Asia-Pacific offers significant growth opportunities due to rising incidence and improving healthcare access.
• Financial Forecast: Sales are projected to increase at a CAGR of approximately 4.2% through 2030, reaching upwards of $340 million annually with continued market penetration.
• Strategic Recommendations: Focus on expanding indications, leveraging collaborations, and navigating reimbursement policies to sustain growth.

---

FAQs

1. How does IXEMPRA KIT compare to other chemotherapy options?
IXEMPRA KIT is specifically designed for resistant metastatic breast cancer, offering efficacy where other chemotherapies may be less effective. Its niche focus and proven activity in resistant cases make it distinct, though it generally carries higher costs.

2. What are the main factors influencing IXEMPRA KIT sales growth?
Key drivers include geographic expansion, approval of new indications, increased adoption in emerging markets, and pipeline developments. Reimbursement policies and competitive pressures significantly influence actual sales.

3. Will generic versions impact IXEMPRA KIT’s market share?
Yes, the entry of biosimilars or generics can reduce pricing and market share. Strategic patent protections and brand recognition mitigate some impacts, but long-term growth may be tempered.

4. How are reimbursement policies affecting IXEMPRA KIT’s market access?
Reimbursement varies by region; favorable policies promote higher utilization, whereas stringent HTA evaluations and cost-containment measures can limit access and sales.

5. What future developments could alter IXEMPRA KIT’s market landscape?
New targeted therapies, combination regimens, and personalized medicine approaches are poised to challenge existing treatments, including IXEMPRA. Regulatory expansions into earlier treatment lines could also modify its role.

---

References

1. Research and Markets. (2023). Global Breast Cancer Therapeutics Market Report.
2. World Health Organization (WHO). (2021). Breast cancer statistics.
3. FDA. (2007). Approval of IXEMPRA (ixabepilone).
4. European Medicines Agency (EMA). Approvals and indications for IXEMPRA.
5. Company financial disclosures and market reports.

Note: All forecasts and data points are estimates based on current trends and publicly available sources.